Projects per year
Fingerprint
Dive into the research topics where John Park is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
C4201002: CTU: A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE-FINDING, PHARMACOKINETIC, SAFETY AND TOLERABILITY STUDY OF PF-07265807 IN PARTICIPANTS WITH SELECTED ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES
Park, J., Chester, C. & Chapman, N.
18/09/22 → 31/03/27
Project: Research
-
D3S-001-100: CTU: A Phase 1, Open Label, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S 001 Monotherapy in Subjects with Advanced Solid Tumors with a KRAS p.G12C Mutation
Park, J., Chester, C. & Chapman, N.
24/08/22 → 13/07/27
Project: Research
-
BAT-7104-002-CR: CTU: A Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT7104 in Patients with Advanced Solid Tumours
Park, J., Chester, C. & Chapman, N.
23/06/22 → 30/03/27
Project: Research
-
VT3996-301: CTU: An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and in Combination with Pembrolizumab in Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma
Park, J., Chapman, N. & Chester, C.
21/06/22 → 27/04/27
Project: Research
-
ADG126-1001: CTU: A First-in-Human (FIH), Open-Label, Phase I Dose Escalation and Expansion Study of ADG126, ADG126 in Combination with Toripalimab, and ADG126 in Combination with ADG106 in Patients with Advanced/Metastatic Solid Tumors
Park, J., Chapman, N. & Chester, C.
25/05/22 → 26/05/27
Project: Research
-
Clinical models to define response and survival with anti-PD-1 antibodies alone or combined with ipilimumab in metastatic melanoma
da Silva, I. P., Ahmed, T., McQuade, J. L., Nebhan, C. A., Park, J. J., Versluis, J. M., Serra-Bellver, P., Khan, Y., Slattery, T., Oberoi, H. K., Ugurel, S., Haydu, L. E., Herbst, R., Utikal, J., Pfohler, C., Terheyden, P., Weichenthal, M., Gutzmer, R., Mohr, P., Rai, R. & 14 others, , 1 Apr 2022, In: Journal of Clinical Oncology. 40, 10, p. 1068-1080 15 p.Research output: Contribution to journal › Article › peer-review
3 Citations (Scopus) -
Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series
Smith, J. L., Menzies, A. M., Cohen, J. V., Mut-Lloret, M., Ozgun, A., Spain, L., Park, J., Quach, H. T., Pallan, L., McQuade, J., Feng, S., Sandhu, S., Atkinson, V., Tsai, K., Long, G. V., Larkin, J., Eroglu, Z., Johnson, D. B., Sullivan, R., Herkes, G. K. & 2 others, , 1 Dec 2022, In: Melanoma Research. 32, 6, p. 451-459 9 p.Research output: Contribution to journal › Article › peer-review
-
Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling
Park, J. J., Stewart, A., Irvine, M., Pedersen, B., Ming, Z., Carlino, M. S., Diefenbach, R. J. & Rizos, H., Oct 2022, In: Cancer Gene Therapy. 29, 10, p. 1384-1393 10 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile1 Citation (Scopus)1 Downloads (Pure) -
Circulating tumor DNA reflects uveal melanoma responses to protein kinase C inhibition
Park, J. J., Diefenbach, R. J., Byrne, N., Long, G. V., Scolyer, R. A., Gray, E. S., Carlino, M. S. & Rizos, H., 1 Apr 2021, In: Cancers. 13, 7, p. 1-14 14 p., 1740.Research output: Contribution to journal › Article › peer-review
Open AccessFile9 Citations (Scopus)3 Downloads (Pure) -
The impact of nonsteroidal anti-inflammatory drugs, beta blockers, and metformin on the efficacy of anti-PD-1 therapy in advanced melanoma
Wang, D. Y., McQuade, J. L., Rai, R. R., Park, J. J., Zhao, S., Ye, F., Beckermann, K. E., Rubinstein, S. M., Johnpulle, R., Long, G. V., Carlino, M. S., Menzies, A. M., Davies, M. A. & Johnson, D. B., 1 Mar 2020, In: Oncologist. 25, 3, p. e602-e605 4 p.Research output: Contribution to journal › Article › peer-review
Open Access25 Citations (Scopus)